Argenx Se (ARGX) Growth Rates Comparisons to Biotechnology & Pharmaceuticals Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Argenx Se  (NASDAQ: ARGX)
 

Argenx Se Growth Comparisons

Select each growth Category to receive further Information





ARGX Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q4 MRQ) 89.08 % 7.78 % 8.07 % 9.17 %
Q / Q Revenue Growth (Q4 MRQ) - 3.44 % 1.81 % 4.22 %
Y / Y Revenue Growth (for 12 months ending Q4 TTM) 89.08 % 10.53 % 7.04 % %
Sequential Revenue Growth (for 12 months ending Q4 TTM) - 6.05 % 3.51 % 2.08 %
Revenue 5 Year Average Growth 189.59 % 8.2 % 8.65 % 10.59 %


ARGX's Growth Comparisons in IV. Quarter 2025




Strong but slowing Revenue rise by Argenx Se of 89.08% year on year , in the fourth quarter 2025 to 8.40 billions, was higher than the 7.78% growth in the Biotechnology & Pharmaceuticals industry, and 8.07% growth in the Healthcare sector. Despite modest Sales rises in the Healthcare sector and in the Biotechnology & Pharmaceuticals industry, Argenx Se reported above average market Sales growth.

Sequentially company's Revenue were unchanged from the third quarter results. . Looking into annual growth, sales grew by 189.59% on average in last five years, while S & P 500's including only Businesses with the fourth quarter 2025 earnings reports, average yearly sales growth is 10.59%.

ARGX Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
United States
-
-
Japan
-
-
China
-
-
Rest of the World
-
-
Total
-
-


Growth Rates of ARGX's Income in the fourth quarter 2025


ARGX Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q4 MRQ) - 64.58 % 27.58 % 29.95 %
Sequential Operating Income Change (Q4 MRQ) - -0.43 % -17.75 % 4.5 %
Y / Y Operating Income Growth (Q4 TTM) - - 37.01 % 14.37 %
Sequential Operating Income Growth (Q4 TTM) - 51.59 % 9.74 % 6.96 %
Operating Income 5 Year Avg. Change - -18.41 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q4 MRQ) 55.1 % - - 21.83 %
Sequential Income from Cont. Ops. Change (Q4 MRQ) - - - 11.13 %
Y / Y Income from Cont. Ops. Change (Q4 TTM) 55.1 % - -25.13 % 16.46 %
Sequential Income from Cont. Ops. Change (Q4 TTM) 55.1 % -81.85 % -6.43 % 6.05 %
Income from Cont. Ops. 5 Year Avg. Change - -11.5 % 0.17 % -28.52 %

ARGX Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q4 MRQ) 55.1 % - 16.75 % 21.56 %
Q / Q Net Income Growth (Q4 MRQ) - -57.17 % -34.35 % 11.12 %
Y / Y Net Income Change (Q4 TTM) 55.1 % - 32.74 % 16.59 %
Sequential Net Income Change (Q4 TTM) 55.1 % 32.56 % 7.31 % 6.03 %
Net Income 5 Year Avg. Growth - -8.55 % 9.21 % 22.96 %

ARGX's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q4 MRQ) - - - 21.83 %
Sequential EPS from Cont. Ops. Change (Q4 MRQ) - - - 11.13 %
Y / Y EPS from Cont. Ops. Change (Q4 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q4 TTM) - - - -99.7 %
EPS from Cont. Ops. 5 Year Avg. Growth - 49.32 % 0.17 % -28.52 %



ARGX EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q4 MRQ) - - 16.75 % -28.52 %
Q / Q EPS Net Growth (Q4 MRQ) - -57.32 % -34.35 % 11.12 %
Y / Y EPS Net Change (for 12 months ending Q4 TTM) - - - -99.97 %
Sequential EPS Net Change (for 12 months ending Q4 TTM) - - - -99.87 %
EPS Net 5 Year Avg. Change - -8.55 % 9.21 % 22.96 %



Argenx Se reported bottom-line of $ 0.00 in the fourth quarter, compare to $ 0.00 in the same quarter a year ago. Biotechnology & Pharmaceuticals industry grew by 7.78%, while Healthcare sector increased by 16.75%, and overall market improved by 21.56%.

Sequentially company's EPS were unchanged from the third quarter results. . Looking into annual growth, income per share grew by 189.59% on average in the last five years, while the S & P 500's including only the businesses with the fourth quarter 2025 financial results, average yearly income per share growth is 22.96%.

ARGX Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q4 MRQ) - -28.32 % -10.43 % 2 %
Sequential Free Cash Flow Change (Q4 MRQ) - -31.91 % -28.83 % 22.32 %
Y / Y Free Cash Flow Change (Q4 TTM) - 3.36 % 11.09 % 11.81 %
Sequential Free Cash Flow Change (Q4 TTM) - -4.03 % 1.93 % 2.41 %
Free Cash Flow 5 Year Avg. Change - -14.51 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q4 MRQ) - -80.06 % -88.83 % 1035.72 %
Sequential Net Cash Flow Change (Q4 MRQ) - -64.86 % -98.87 % -
Y / Y Net Cash Flow Change (Q4 TTM) - -50.79 % -23.28 % -
Sequential Net Cash Flow Change (Q4 TTM) - -47.77 % -25.11 % -
Net Cash Flow 5 Year Avg. Change 35.26 % 23.25 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q4 MRQ) 242.31 % -14.5 % 9.45 % 23.41 %
Sequential Capital Expenditures Change (Q4 MRQ) - 38.91 % 18.78 % 18.97 %
Y / Y Capital Expenditures Change (Q4 TTM) 242.31 % -13.93 % 10.57 % 23.88 %
Sequential Capital Expenditures Change (Q4 TTM) 242.31 % -9.69 % 6.56 % 7.02 %
Capital Expenditures 5 Year Avg. Change - 9.64 % 8.61 % 14.74 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.